Dianthus Therapeutics (DNTH) Operating Expenses (2017 - 2025)

Dianthus Therapeutics has reported Operating Expenses for 9 years, with the latest figure at $40.7 million in Q3 2025.

• For the quarter ending Q3 2025, Operating Expenses rose 26.85% year-over-year to $40.7 million; the trailing twelve-month figure through Dec 2025 stood at $110.1 million (up 1.89% YoY), and the FY2024 full-year result was $108.1 million, up 111.96% from the prior year.
• Operating Expenses for Q3 2025 stood at $40.7 million, up from $35.1 million in the prior quarter.
• The five-year high for Operating Expenses was $40.7 million in Q3 2025, with the low at $8.2 million in Q1 2023.
• Average Operating Expenses over 5 years is $21.4 million, with a median of $18.7 million recorded in 2021.
• Year-over-year, Operating Expenses slumped 65.77% in 2023 and jumped 147.83% in 2024.
• Tracing DNTH's Operating Expenses over 5 years: stood at $20.1 million in 2021, then tumbled by 41.07% to $11.9 million in 2022, then climbed by 13.02% to $13.4 million in 2023, then jumped by 147.83% to $33.2 million in 2024, then grew by 22.39% to $40.7 million in 2025.
• The last three Operating Expenses figures came in at $40.7 million (Q3 2025), $35.1 million (Q2 2025), and $34.3 million (Q1 2025), per Business Quant data.

Peer Comparison